LeMaitre Vascular, Inc.
(NASDAQ: LMAT)

LeMaitre Vascular, Inc. (LeMaitre Vascular) is a global provider of medical devices and implants for the treatment of peripheral vascular disease. The Company develops, manufacture, and market vascular devices to addresses the needs of vascular surgeons. The Company's diversified portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart and are well known to vascular surgeons, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, and VascuTape Radiopaque Tape. The Company sells 12 product lines, most of which are used in open vascular surgery and some of which are used in endovascular procedures. The Company sells its products primarily through a direct sales force. In August 2014, the Company acquired Xenotis, the manufacturer and marketer of the Omniflow II biological graft for peripheral bypass and dialysis access

85.700 s

+0.780 (+0.92%)
Range 83.160 - 86.790   (4.37%)
Open 84.550
Previous Close 84.920
Bid Price 59.880
Bid Volume 9
Ask Price 60.260
Ask Volume 9
Volume 230,648
Value -
Remark s
Delayed prices. Updated at 05 Dec 2025 05:00.
Data powered by
View All Events

About LeMaitre Vascular

LeMaitre Vascular, Inc. (LeMaitre Vascular) is a global provider of medical devices and implants for the treatment of peripheral vascular disease. The Company develops, manufacture, and market vascular devices to addresses the needs of vascular surgeons. The Company's diversified portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart and are well known to vascular surgeons, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, and VascuTape Radiopaque Tape. The Company sells 12 product lines, most of which are used in open vascular surgery and some of which are used in endovascular procedures. The Company sells its products primarily through a direct sales force. In August 2014, the Company acquired Xenotis, the manufacturer and marketer of the Omniflow II biological graft for peripheral bypass and dialysis access

Loading Chart...

Please login to view stock data and analysis